Liver-expressed antimicrobial peptide 2
Preclinical
Liver-expressed antimicrobial peptide 2 is one of 12 therapeutic programs targeting Obesity & Overweight. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
13 competitors in Obesity & Overweight
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Ozempic
Novo NordiskPhase 2
Crestor
AstraZenecaPreclinical
Semagludtide
Novo NordiskPhase 2
LUM-201
LLumos Pharma
Phase 2
Enobosarm
VVeru Inc.
Phase 2
Spermidine
MMedical University of Graz
Preclinical
Incretin-Based Treatment
JJohns Hopkins University
Preclinical
GLP-1 Receptor Agonist Therapy
GGazi University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]